// App-Quantinova.ai

PO0357 : A Real-World Observational Study of Calcimimetic Use in Hemodialysis (HD) Patients with Secondary Hyperparathyroidism (SHPT) in Europe

Researchers

Presenter

  • Fouqueray Bruno

Principal Investigators

  • Louie KarlyS

  • Kohnle Matthias

  • Cejka Daniel

  • Piccoli GiorginaB

  • Rix Marianne

  • Camerini Corrado

  • Boots JohannesMartinus maria

  • Marn Pernat Andreja

  • Labriola Laura

  • Torregrosa Jose-Vicente

  • Nduka ChidozieU

  • Tsirtsonis Kate

  • Floege Jrgen

Medical Centers

  • Amgen GmbH Rotkreuz Rotkreuz Switzerland

  • Amgen Ltd Uxbridge Uxbridge Middlesex United Kingdom

  • Nephrologisches Zentrum Mettmann Gartenstrasse 8 Mettmann Mettmann Germany

  • Department of Medicine III Division of Nephrology and Dialysis Medical University Vienna Vienna Austria

  • Nephrology, Centre Hospitalier Le Mans, Le Mans, France

  • Department of Biology, University of Copenhagen, Copenhagen, Denmark

  • Azienda AO Spedali Civili di Brescia, Brescia, Italy

  • Department of Internal Medicine and Nephrology Maasstad Hospital the Netherlands Rotterdam Netherlands

  • University Medical Centre Ljubljana, Ljubljana, Slovenia

  • Department of Nephrology Cliniques Universitaires Saint-Luc Universite Catholique de Louvain Brussels Brussels Belgium

  • Nephrology and Renal Transplant Department Hospital Clinic University of Barcelona Barcelona Barcelona Spain

  • Nephrology, RWTH University of Aachen, Aachen, Germany

Locations

  • Switzerland

  • United Kingdom

  • Germany

  • Austria

  • France

  • Denmark

  • Italy

  • Netherlands

  • Slovenia

  • Belgium

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Secondary hyperparathyroidism

Biomarkers

  • Parathyroid Hormone

Drug/Treatment

  • Parathyroid hormone

Outcome

  • N/A


Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A